Sakys John 4
4 · MESA LABORATORIES INC /CO/ · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Mesa Labs (MLAB) CFO John Sakys Exercises Options, Sells Shares
What Happened
- John Sakys, Chief Financial Officer of Mesa Laboratories (MLAB), exercised stock derivatives and received restricted stock units (RSUs) on June 18, 2026, and then sold shares on June 22, 2026.
- He exercised/converted two derivative tranches totaling 3,792 shares at an exercise price of $95.10 (total cash paid ≈ $360,620). He also received 2,282 RSUs valued at $95.10 each (≈ $217,018). Combined, 6,074 shares were acquired/issued with a notional value of about $577,638.
- On June 22, 2026 he sold 2,827 shares in an open‑market transaction at $89.50 per share for proceeds of $253,022. The filing notes the sale was executed under a 10b5‑1 plan to cover taxes related to the vesting of RSUs and PSUs.
Key Details
- Transaction dates/prices: June 18, 2026 (exercise/conversion and RSU award at $95.10); June 22, 2026 (open‑market sale at $89.50).
- Shares acquired: 3,792 via exercise (paid $95.10 each) + 2,282 RSUs (awarded) = 6,074 shares acquired/issued.
- Shares sold: 2,827 shares for $253,022; footnote F6 says sale was to cover taxes and executed under a 10b5‑1 plan.
- Derivative notation: two derivative entries show a $0.00 disposal — these reflect conversion/termination of the derivative instruments upon exercise.
- Ownership after transaction: not specified in the provided filing excerpt.
- Other footnotes: RSU/PSU vesting schedules noted (F2, F4, F5); 50 shares are held by his children for which he is custodian (F7).
- Filing timing: transactions occurred June 18–22 and the Form 4 was filed June 23, 2026. Form 4s are typically required within two business days of a transaction; the June 18 entries appear reported after that window.
Context
- The activity combines an option exercise (insider paid to convert derivatives into shares) plus grant vesting (RSUs/PSUs) and a contemporaneous sale to satisfy tax withholding — a common, non‑directional action.
- Sales executed under a 10b5‑1 plan to cover taxes are routine and do not necessarily indicate a view on company prospects.
- For retail investors, purchases/exercises show insider acquisition of shares, but because part of this was awards vesting and the sale was for tax withholding, the moves should be interpreted as administrative/compensation‑related rather than a clear bullish or bearish signal.
Insider Transaction Report
Form 4
Sakys John
CFO
Transactions
- Exercise/Conversion
Common Stock
2026-06-18$95.10/sh+1,036$98,524→ 17,574 total - Exercise/Conversion
Common Stock
2026-06-18$95.10/sh+2,756$262,096→ 20,330 total - Award
Common Stock
[F5]2026-06-18$95.10/sh+2,282$217,018→ 22,612 total - Sale
Common Stock
[F6]2026-06-22$89.50/sh−2,827$253,022→ 19,785 total - Exercise/Conversion
Restricted Stock Units - 6
[F1][F2][F3]2026-06-18−1,036→ 0 totalFrom: 2024-06-21→ Common Stock (1,036 underlying) - Exercise/Conversion
Restricted Stock Units - 7
[F1][F4][F3]2026-06-18−2,756→ 2,755 totalFrom: 2025-06-18→ Common Stock (2,756 underlying)
Holdings
- 50(indirect: Custodian)
Common Stock
[F7]
Footnotes (7)
- [F1]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F2]RSUs that vested June 21, 2024 and each of the next two anniversary dates
- [F3]Not Applicable
- [F4]RSUs that vest 1/3 on June 15, 2026 and each of the next 2 anniversary dates
- [F5]Shares represent common stock of Mesa Labs issued upon release of performance share units issued under the FY24-FY26 performance share unit program
- [F6]Shares sold to cover taxes related to the vesting of RSUs and PSUs on June 18, 2026. Transaction was executed under a 10b5-1 plan.
- [F7]Consists of 50 shares held by children of which Mr. Sakys is custodian
Signature
John Sakys|2026-06-23